ENTITY
CStone Pharmaceuticals

CStone Pharmaceuticals (2616 HK)

130
Analysis
Health Care • China
CStone Pharmaceuticals is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines for cancer patients. It has launched multiple innovative drugs, including sugemalimab, avapritinib, and pralsetinib, to address unmet medical needs in China and globally. The company was founded in 2015 and is headquartered in Suzhou, China.
more
bullish•Antengene
•06 Nov 2020 07:40

Antengene: Gunning To Move Up in Line

This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...

Share
bullish•Everest Medicines
•24 Oct 2020 23:47

What HKEX Biotech "Step-Ups" Can Tell Us

This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...

Share
bullish•CanSino Biologics
•22 Jul 2020 05:39

HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities

Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...

Logo
1.1k Views
Share
bullish•Burning Rock Biotech
•24 May 2020 16:54

Burning Rock Biotech IPO Initiation: Burning Ambitions

Burning Rock Biotech (BNR US) is a precision oncology and early cancer detection company. It is China’s number one NGS-based cancer therapy...

Logo
455 Views
Share
bullish•InnoCare Pharma
•11 Feb 2020 00:32

InnoCare Pharma IPO Initiation: Promising Prognosis

InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
526 Views
Share
x